AtriCure, Inc.
ATRCNasdaq
$34.95
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↑ +15.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.6B
P/E
—
P/S
3.1
P/B
3.5
EV/EBITDA
180.2
PEG
—
FCF Yield
3.1%
Dividend Yield
—
Revenue (TTM)
$552.2M
Net Income (TTM)
-$4.6M
Free Cash Flow (TTM)
$53.6M
Gross Margin
75.6%
Operating Margin
-0.5%
Net Margin
-0.8%
ROE
-0.9%
ROIC
-0.6%
Debt / Equity
0.1
Net Cash
$85.2M
Return 1Y
+17.5%
Company profile
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue and systems, and intercostal nerves. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products. CryoICE Cryoablation System enables the user to make linear ablations of varied lengths. EPi-Sense Guided Coagulation System is used to treat persistent atrial fibrillation.
- CEO
- Michael H. Carrel
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 1,050
- Headquarters
- Ohio
- Website
- atricure.com
Management & directors
- Carrel Michael HPresident, CEO, & Director
- Dahlquist Karl S.Chief Legal Officer
- Doraiswamy VinayakChief Scientific Officer
- Privitera SalvatoreChief Technical Officer
- Seith Douglas JChief Operating Officer
- Noznesky Justin JChief Mktg & Strategy Officer
- Wirick Angela LChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ATRC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$141.2M↑ +14.3%
Diluted EPS$0.00↓ -100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $206.5M | $274.3M | $330.4M | $399.2M | $465.3M | $534.5M |
| Gross profit | $149.3M | $205.9M | $245.9M | $300.4M | $347.5M | $400.8M |
| Operating income | -$44.2M | $55.2M | -$42.7M | -$26.7M | -$40.0M | -$9.4M |
| Net income | -$48.2M | $50.2M | -$46.5M | -$30.4M | -$44.7M | -$11.4M |
| Diluted EPS | -$1.14 | $1.09 | -$1.02 | -$0.66 | -$0.95 | -$0.24 |
| Operating cash flow | -$19.9M | -$13.8M | -$22.1M | $4.5M | $12.2M | $57.3M |
| Free cash flow | -$25.1M | -$23.5M | -$39.0M | -$7.5M | $745,000.00 | $48.3M |
| Gross margin | 72.3% | 75.0% | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating margin | -21.4% | 20.1% | -12.9% | -6.7% | -8.6% | -1.8% |
| Net margin | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $116.3M | $115.9M | $124.3M | $123.6M | $136.1M | $134.3M | $140.5M | $141.2M |
| Gross profit | $86.8M | $86.8M | $92.6M | $92.6M | $101.5M | $101.3M | $105.3M | $109.3M |
| Operating income | -$7.2M | -$7.4M | -$14.5M | -$6.0M | -$6.2M | $208,000.00 | $2.5M | $526,000.00 |
| Net income | -$8.0M | -$7.9M | -$15.6M | -$6.7M | -$6.2M | -$267,000.00 | $1.8M | $108,000.00 |
| Diluted EPS | -$0.17 | -$0.17 | -$0.33 | -$0.14 | -$0.13 | -$0.01 | $0.04 | $0.00 |
| Operating cash flow | $7.4M | $20.0M | $5.8M | -$11.0M | $21.6M | $26.7M | $20.0M | -$4.0M |
| Free cash flow | $5.0M | $16.4M | $3.1M | -$13.2M | $19.0M | $24.1M | $18.4M | -$7.8M |
| Gross margin | 74.7% | 74.9% | 74.5% | 74.9% | 74.5% | 75.5% | 75.0% | 77.4% |
| Operating margin | -6.2% | -6.4% | -11.7% | -4.8% | -4.5% | 0.2% | 1.8% | 0.4% |
| Net margin | -6.9% | -6.8% | -12.5% | -5.5% | -4.5% | -0.2% | 1.2% | 0.1% |
Company news
Jun 19, 2026
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | CARREL MICHAEL H· President, CEO, & Director | Award | 636 | $23.78 | $15,124.08 | filing |
| 2026-06-30 | Privitera Salvatore· Chief Technical Officer | Award | 636 | $23.78 | $15,124.08 | filing |
| 2026-06-30 | Doraiswamy Vinayak· Chief Scientific Officer | Award | 636 | $23.78 | $15,124.08 | filing |
| 2026-06-30 | Dahlquist Karl S.· Chief Legal Officer | Award | 636 | $23.78 | $15,124.08 | filing |
| 2026-06-30 | Seith Douglas J· Chief Operating Officer | Award | 527 | $23.78 | $12,532.06 | filing |
| 2026-05-20 | Prange Karen | Sale | 3,000 | $28.65 | $85,950.00 | filing |
| 2026-05-18 | WEHRWEIN SVEN | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | WHITE ROBERT S. | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | Nachman Shlomo | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | Prange Karen | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | Telman Deborah H | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | Yuen Maggie | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | JOHNSON B KRISTINE | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | GROVES REGINA E | Award | 6,144 | $0.00 | $0.00 | filing |
| 2026-05-15 | Doraiswamy Vinayak· Chief Scientific Officer | Sale | 5,000 | $28.13 | $140,650.00 | filing |
| 2026-03-12 | Doraiswamy Vinayak· Chief Scientific Officer | Sale | 5,000 | $29.83 | $149,150.00 | filing |
| 2026-03-10 | WHITE ROBERT S. | Option exercise | 10,000 | $14.99 | $149,900.00 | filing |
| 2026-03-06 | CARREL MICHAEL H· President, CEO, & Director | Gift | 5,000 | $0.00 | $0.00 | filing |
| 2026-03-06 | CARREL MICHAEL H· President, CEO, & Director | Gift | 1,000 | $0.00 | $0.00 | filing |
| 2026-03-01 | CARREL MICHAEL H· President, CEO, & Director | Tax withholding | 72,777 | $31.26 | $2.3M | filing |
| 2026-03-01 | Wirick Angela L· Chief Financial Officer | Tax withholding | 22,965 | $31.26 | $717,885.90 | filing |
| 2026-03-01 | Seith Douglas J· Chief Operating Officer | Tax withholding | 22,948 | $31.26 | $717,354.48 | filing |
| 2026-03-01 | Dahlquist Karl S.· Chief Legal Officer | Tax withholding | 15,687 | $31.26 | $490,375.62 | filing |
| 2026-03-01 | Noznesky Justin J· Chief Mktg & Strategy Officer | Tax withholding | 15,586 | $31.26 | $487,218.36 | filing |
| 2026-03-01 | Doraiswamy Vinayak· Chief Scientific Officer | Tax withholding | 15,585 | $31.26 | $487,187.10 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.